Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Metastatic melanoma has a poor prognosis with high resistance to chemotherapy and radiation. Recently, the anti-CTLA-4 antibody ipilimumab has demonstrated clinical efficacy, being the first agent to significantly prolong the overall survival of inoperable stage III/IV melanoma patients. A major aim of patient immune monitoring is the identification of biomarkers that predict clinical outcome. We studied circulating myeloid-derived suppressor cells (MDSC) in ipilimumab-treated patients to detect alterations in the myeloid cell compartment and possible correlations with clinical outcome. Lin(-) CD14(+) HLA-DR(-) monocytic MDSC were enriched in peripheral blood of melanoma patients compared to healthy donors (HD). Tumor resection did not significantly alter MDSC frequencies. During ipilimumab treatment, MDSC frequencies did not change significantly compared to baseline levels. We observed high inter-patient differences. MDSC frequencies in ipilimumab-treated patients were independent of baseline serum lactate dehydrogenase levels but tended to increase in patients with severe metastatic disease (M1c) compared to patients with metastases in skin or lymph nodes only (M1a), who had frequencies comparable to HD. Interestingly, clinical responders to ipilimumab therapy showed significantly less lin(-) CD14(+) HLA-DR(-) cells as compared to non-responders. The data suggest that the frequency of monocytic MDSC may be used as predictive marker of response, as low frequencies identify patients more likely benefitting from ipilimumab treatment. Prospective clinical trials assessing MDSC frequencies as potential biomarkers are warranted to validate these observations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“both a low baseline frequency of MDSCs and a low frequency of MDSCs in the blood of patients with melanoma following ipilimumab treatment were associated with favorable therapy outcome (134, 169-171).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“patients with cancer who have high levels of circulating MDSCs have been found to respond poorly to checkpoint blockade”
From LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer (2018) · cites this paper as Meyer et al., 2014
Experimental — accuracy not yet measuredIn the citing paper
“lower numbers of MDSCs in melanoma patients were associated with a better response to Ipilimumab (CTLA-4 antibody) (Meyer et al., 2014).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Meyer et al., 2014
In the citing paper
“numerous studies of patients with cancer have indeed found that these myeloid cell subsets, whether in the tumor or in peripheral tissues, were negatively correlated with effective ICI therapy (134, 161, 168-171).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [169]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 5×
“However, autoimmune responses are also promoted, as 10–15 % of patients develop severe grade 3–4 immune-related adverse events [8].”
BackgroundInfluentialThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“Recently, the fully humanized anti-CTLA-4 antibody ipilimumab was reported to increase overall survival of stage III/IV metastatic melanoma patients [8, 9].”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“Different malignancies favor the accumulation of different MDSC phenotypes in patients [29].”
BackgroundWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · cited 1×
“About 50 % of melanomas express BRAF-activating mutations [4], which are V600E and V600K substitutions in 95 % of cases [5].”
Background
Cited by
Items 301–400 of 617
Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy
Apollonio, B., Ioannou, N., Papazoglou, D., & Ramsay, A. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626818 · Cited by 31
Ostrand‐Rosenberg, S., Huecksteadt, T. P., & Sanders, K. A. (2023) · Cancers · doi:10.3390/cancers15041026 · Cited by 31
Wong, R. S. J., Ong, R. J. M., & Lim, J. S. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.58 · Cited by 31
Sakata, Y., Kawamura, K., Ichikado, K., Shingu, N., Yasuda, Y. U., Eguchi, Y., Hisanaga, J., Nitawaki, T., Iio, M., Sekido, Y., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13214 · Cited by 31
Heine, A., Flores, C., Gevensleben, H., Diehl, L., Heikenwälder, M. F., Ringelhan, M., Janssen, K., Nitsche, U., Garbi, N., Brossart, P., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1338995 · Cited by 31
Zhu, Y., Zhao, F., Li, Z., & Yu, J. (2018) · Cancer Management and Research · doi:10.2147/cmar.s167400 · Cited by 30
Mortara, L., Benest, A. V., Bates, D. O., & Noonan, D. M. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.009 · Cited by 30
Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges
Pilla, L., & Maccalli, C. (2018) · Biomedicines · doi:10.3390/biomedicines6030076 · Cited by 30
Protein kinase Cι mediates immunosuppression in lung adenocarcinoma
Yin, N., Liu, Y., Weems, C. R., Shreeder, B., Lou, Y., Knutson, K. L., Murray, N. R., & Fields, A. P. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq5931 · Cited by 30
Lee, S., Lim, J., Kim, T. W., Ryu, D., Park, S. S., Jeon, Y., Yoon, J., Cho, B., Eom, K., Kim, Y., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0491-y · Cited by 30
Tengesdal, I. W., Li, S., Powers, N. E., May, M., Neff, C. P., Joosten, L. A. B., Marchetti, C., & Dinarello, C. A. (2022) · Pharmaceuticals · doi:10.3390/ph15050574 · Cited by 30
Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma
Foley, K. C., Nishimura, M. I., & Moore, T. V. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000436 · Cited by 29
Combined Effects of Myeloid Cells in the Neuroblastoma Tumor Microenvironment
Frosch, J., Leontari, I., & Anderson, J. (2021) · Cancers · doi:10.3390/cancers13071743 · Cited by 29
Hutchison, S., Sahay, B., de Mello, S. C., Sayour, E. J., Lejeune, A. T., Szivek, A., Livaccari, A., Fox‐Alvarez, S. A., Salute, M. E., Powers, L., et al. (2019) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2019.109912 · Cited by 29
Krebs, F. K., Trzeciak, E. R., Zimmer, S., Özistanbullu, D., Mitzel-Rink, H., Meißner, M., Grabbe, S., Loquai, C., & Tuettenberg, A. (2021) · Cancer Medicine · doi:10.1002/cam4.3710 · Cited by 29
Yang, Z., Liang, A.-B., & Ansell, S. M. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1011640 · Cited by 29
Hirano, K., Hosoi, A., Matsushita, H., Iino, T., Ueha, S., Matsushima, K., Seto, Y., & Kakimi, K. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1019195 · Cited by 29
Chae, Y. K., Oh, M. S., & Giles, F. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0354 · Cited by 28
TAM kinase inhibition and immune checkpoint blockade– a winning combination in cancer treatment?
Msaouel, P., Genovese, G., Gao, J., Sen, S., & Tannir, N. M. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1869212 · Cited by 28
The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy
Amara, S., & Tiriveedhi, V. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030650 · Cited by 27
Immunotherapeutic targets in non‐small cell lung cancer
Sadeghirad, H., Bahrami, T., Layeghi, S. M., Yousefi, H., Rezaei, M., Hosseini‐Fard, S. R., Radfar, P., Warkiani, M. E., O'Byrne, K. J., & Kulasinghe, A. (2022) · Immunology · doi:10.1111/imm.13562 · Cited by 27
Tomela, K., Pietrzak, B., SCHMIDT, M. T., & Mackiewicz, A. A. (2020) · Life · doi:10.3390/life10100219 · Cited by 26
New Immuno-oncology Targets and Resistance Mechanisms
Tokaz, M. C., Baik, C. S., Houghton, A. M., & Tseng, D. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01005-8 · Cited by 26
Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
Tomela, K., Pietrzak, B., Galus, Ł., Mackiewicz, J., SCHMIDT, M. T., Mackiewicz, A. A., & Kaczmarek, M. (2023) · Cells · doi:10.3390/cells12050789 · Cited by 26
Drug Resistance in Cancers: A Free Pass for Bullying
Li, J., Li, X., & Guo, Q. (2022) · Cells · doi:10.3390/cells11213383 · Cited by 26
Combinations using checkpoint blockade to overcome resistance
Morganti, S., & Curigliano, G. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1148 · Cited by 26
p110δ PI3K as a therapeutic target of solid tumours
Xenou, L., & Papakonstanti, E. A. (2020) · Clinical Science · doi:10.1042/cs20190772 · Cited by 26
Schröder, M., Krötschel, M., Conrad, L., Naumann, S. K., Bachran, C., Rolfe, A., Umansky, V., Helming, L., & Swee, L. K. (2018) · Scientific Reports · doi:10.1038/s41598-018-31674-1 · Cited by 26
Senescence and Aging: Does It Impact Cancer Immunotherapies?
Maggiorani, D., & Beausejour, C. M. (2021) · Cells · doi:10.3390/cells10071568 · Cited by 25
Highlights on immune checkpoint inhibitors in non–small cell lung cancer
Shen, M., & Ren, X. (2017) · Tumor Biology · doi:10.1177/1010428317695013 · Cited by 25
Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more
Shibata, M., Nanno, K., Yoshimori, D., Nakajima, T., Takada, M., Yazawa, T., Mimura, K., Inoue, N., Watanabe, T., Tachibana, K., et al. (2022) · Oncotarget · doi:10.18632/oncotarget.28303 · Cited by 25
Stanojević, I., Miller, K., Sekulović, L. K., Mijušković, Ž. P., Zolotarevski, L. D., Jović, M., Gacevic, M., Djukic, M. M., Arsenijević, N., & Vojvodić, D. (2015) · International Immunology · doi:10.1093/intimm/dxv053 · Cited by 25
Zheng, A., Xie, F. X., Shi, S., Liu, S., Long, J., & Xu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.829391 · Cited by 24
Seyhan, A. A., & Carini, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010041 · Cited by 24
TLR8 ligation induces apoptosis of monocytic myeloid-derived suppressor cells
Dang, Y., Rutnam, Z. J., Dietsch, G. N., Lu, H., Yang, Y., Hershberg, R. M., & Disis, M. L. (2017) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ab0217-070r · Cited by 24
Lauko, A. J., Thapa, B., Sharma, M., Muhsen, B. A., Barnett, A. E., Rauf, Y., Borghei-Razavi, H., Tatineni, V., Patil, P. D., Mohammadi, A. M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85328-w · Cited by 24
Sheng, I. Y. F., Diaz-Montero, C. M., Rayman, P. A., Wei, W., Finke, J. H., Kim, J. S., Pavicic, P. G., Lamenza, M., Stephenson, A. J., Campbell, S. C., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00707-z · Cited by 24
Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma
García‐Sancha, N., Corchado‐Cobos, R., Bellido-Hernández, L., Román‐Curto, C., Álvarez, E. C., Pérez‐Losada, J., Órfão, A., & Cañueto, J. (2021) · Cancers · doi:10.3390/cancers13205134 · Cited by 23
Hu, B., Wei, Q., Zhou, C., Ju, M., Wang, L., Chen, L., Li, Z., Wei, M., He, M., & Zhao, L. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107162 · Cited by 23
Lin, M., Chuang, Y., Wu, H., Hsu, C., Lin, N., Huang, M., & Lou, P. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13489 · Cited by 23
D’Arrigo, P., Tufano, M., Rea, A., Vigorito, V., Novizio, N., Russo, S., Romano, M. F., & Romano, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181106114421 · Cited by 23
Melanoma immunotherapy: strategies to overcome pharmacological resistance
Trojaniello, C., Vitale, M. G., Scarpato, L., Esposito, A., & Ascierto, P. A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1745634 · Cited by 23
Clinical correlates for immune checkpoint therapy: significance for CNS malignancies
Ratnam, N. M., Frederico, S. C., Gonzalez, J., & Gilbert, M. R. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa161 · Cited by 23
Immunotherapy for advanced melanoma: Current knowledge and future directions
Nakamura, K., & Okuyama, R. (2016) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2016.05.009 · Cited by 23
Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile
Zhao, Q., Hu, J., Mitra, A., Cutrera, J. J., Zhang, W., Zhang, Z., Yan, J., Xia, X., Mahadeo, K. M., Livingston, J. A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0631-z · Cited by 23
Gondois‐Rey, F., Paul, M., Alcaraz, F., Bourass, S., Monnier, J., Malissen, N., Grob, J., Bruger, A. M., van der Bruggen, P., Gaudy‐Marqueste, C., et al. (2021) · Cancers · doi:10.3390/cancers13061362 · Cited by 22
Nair, N., Chen, S.-Y., Lemmens, E., Chang, S., Le, D. T., Jaffee, E. M., Murphy, A. L., Whiting, C. C., Müller, T., & Brockstedt, D. G. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0650 · Cited by 22
Biomarkers for predicting the outcome of various cancer immunotherapies
Jafarzadeh, L., Khakpoor-Koosheh, M., Mirzaei, H., & Mirzaei, H. R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103161 · Cited by 22
Yin, X., Wu, T., Lan, Y., & Yang, W. (2022) · Bioscience Reports · doi:10.1042/bsr20212304 · Cited by 22
Tilsed, C. M., Casey, T. H., de Jong, E., Bosco, A., Zemek, R. M., Salmons, J., Wan, G., Millward, M., Nowak, A. K., Lake, R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.849793 · Cited by 22
Akanda, Z. Z., Neeson, P. J., John, T., Barnett, S. A., Hanna, G. G., Miller, A., Jennens, R. R., & Siva, S. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1117 · Cited by 22
Chen, J.-S., Chou, C.-H., Wu, Y.-H., Yang, M.-H., Chu, S.-H., Chao, Y.-S., & Chen, C.-N. (2022) · Scientific Reports · doi:10.1038/s41598-022-05055-8 · Cited by 22
Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies
Weide, B., Di Giacomo, A. M., Fonsatti, E., & Zitvogel, L. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.016 · Cited by 21
Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors
Ma, K., Jin, Q., Wang, M., Li, X., & Zhang, Y. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1617702 · Cited by 21
A Perspective on Therapeutic Pan-Resistance in Metastatic Cancer
Korentzelos, D. K., Clark, A. M., & Wells, A. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197304 · Cited by 21
Interplay between inflammasomes and PD-1/PD-L1 and their implications in cancer immunotherapy
Jiao, Z., & Zhang, J. (2023) · Carcinogenesis · doi:10.1093/carcin/bgad072 · Cited by 21
Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
Rodríguez-Pascual, J., Ayuso‐Sacido, Á., & Belda-Iniesta, C. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.61 · Cited by 21
Sammarco, E., Manfredi, F., Nuzzo, A., Ferrari, M., Bonato, A., Salfi, A., Serafin, D., Zatteri, L., Antonuzzo, A., & Galli, L. (2023) · Cancers · doi:10.3390/cancers15123172 · Cited by 21
Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy
Margolis, N., Markovits, E., & Markel, G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.005 · Cited by 20
Wang, J., Loeuillard, E. J., Gores, G. J., & Ilyas, S. I. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2010046 · Cited by 20
Watson, G. A., Doi, J., Hansen, A. R., & Spreafico, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14355 · Cited by 20
Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer
Shen, Q., Murakami, K., Sotov, V., Butler, M. O., Ohashi, P. S., & Reedijk, M. (2024) · Science Advances · doi:10.1126/sciadv.ado8275 · Cited by 20
Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
Khononov, I., Jacob, E., Fremder, E., Dahan, N., Harel, M., Raviv, Z., Krastev, B. M., & Shaked, Y. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001996 · Cited by 20
The Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis
Bayık, D., Lee, J., & Lathia, J. D. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_7 · Cited by 20
Guglietta, S., & Krieg, C. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101012 · Cited by 20
Bai, R., Li, L., Chen, X., Chen, N., Song, W., Zhang, Y., Lv, Z., Han, F., Zhao, Y., Li, W., et al. (2021) · Journal of Oncology · doi:10.1155/2021/9935076 · Cited by 20
Blood-based analyses of cancer: Circulating myeloid-derived suppressor cells – is a new era coming?
Okła, K., Wertel, I., Wawruszak, A., Bobiński, M. S., & Kotarski, J. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1477729 · Cited by 20
Sivagnanalingam, U., Beatty, P. L., & Finn, O. J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23206 · Cited by 20
Huang, Y., Zhao, J. J., Soon, Y. Y., Kee, A. C.-L., Tay, S. H., Aminkeng, F., Ang, Y. L. E., Wong, A. S. C., Bharwani, L. D., Goh, B. C., et al. (2023) · Cancers · doi:10.3390/cancers15102733 · Cited by 20
Extracellular Vesicles Secreted by Tumor Cells Promote the Generation of Suppressive Monocytes
Luong, N., Lenz, J., Modiano, J. F., & Olson, J. K. (2021) · ImmunoHorizons · doi:10.4049/immunohorizons.2000017 · Cited by 20
Biomarkers of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer: Beyond PD-L1
Cabezón‐Gutiérrez, L., Custodio‐Cabello, S., Palka-Kotlowska, M., Viteri, S. A., & Khosravi‐Shahi, P. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.03.006 · Cited by 19
Lee, Y. J., Lee, J. B., Ha, S., & Kim, H. R. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0044 · Cited by 19
Imperfect Predictors for Lung Cancer Immunotherapy—A Field for Further Research
Wojas‐Krawczyk, K., & Kubiatowski, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568174 · Cited by 19
Chevolet, I., Schreuer, M. S., Speeckaert, R., Neyns, B., Hoorens, I., van Geel, N., Krüse, V., Hennart, B., Allorge, D., Gele, M. V., et al. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000171 · Cited by 19
Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors
Zhang, X., Li, H., Lv, X., Hu, L., Li, W., Zi, M., & He, Y. (2022) · Life · doi:10.3390/life12030409 · Cited by 18
Drug resistance mechanism and reversal strategy in lung cancer immunotherapy
Xu, Y., Liu, Y., Ge, Y., Li, H., Zhang, Y., & Wang, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1230824 · Cited by 18
Ledermann, J. A., Shapira‐Frommer, R., Santin, A. D., Lisyanskaya, A. S., Pignata, S., Vergote, I. B., Raspagliesi, F., Sonke, G. S., Birrer, M. J., Provencher, D. M., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.09.012 · Cited by 18
Paschold, L., Schultheiß, C., Schmidt-Barbo, P., Klinghammer, K. F., Hahn, D., Tometten, M., Schafhausen, P., Blaurock, M., Brandt, A. P., Westgaard, I., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01020-6 · Cited by 18
Zhang, H., Lu, X., Lu, B., Gullo, G., & Chen, L. (2024) · Future Oncology · doi:10.2217/fon-2023-0658 · Cited by 18
Wong, S. W., McCarroll, J. A., Hsu, K., Geczy, C. L., & Tedla, N. T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.826391 · Cited by 18
Liu, J., Cai, Y., Liu, J., Chen, D., & Wu, X. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s539978 · Cited by 18
Cancer Neoantigens: A Promising Source of Immunogens for Cancer Immunotherapy
Kitano, A. I. S. (2015) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000322 · Cited by 18
Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
Bobrowicz, M., Zagożdżon, R., Domagała, J., Vasconcelos‐Berg, R., Guenova, E., & Winiarska, M. (2019) · Cancers · doi:10.3390/cancers11101420 · Cited by 17
Immune Signatures and Survival of Patients With Metastatic Melanoma, Renal Cancer, and Breast Cancer
Wistuba‐Hamprecht, K., Gouttefangeas, C., Weide, B., & Pawelec, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01152 · Cited by 17
Khunger, A., Sarikonda, G., Tsau, J., Pahuja, A., Alfonso, Z., Gao, J., Laing, C., Vaupel, C., Dakappagari, N. K., & Tarhini, A. A. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101014 · Cited by 17
Jackson, J. J., Shibuya, G. M., Ravishankar, B., Adusumilli, L., Bradford, D., Brockstedt, D. G., Bucher, C., Bui, M., Cho, C., Colas, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00736 · Cited by 17
High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy
Quek, C. Y. J., Bai, X., Long, G. V., Scolyer, R. A., & Wilmott, J. S. (2021) · Genes · doi:10.3390/genes12101629 · Cited by 16
Wu, Y., Yu, S., & Qiao, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.990445 · Cited by 16
Ma, W., Wei, S., Long, S., Tian, E. C., McLaughlin, B. E., Jaimes, M. C., Montoya, D. J., Viswanath, V. R., CHIEN, J. R., Zhang, Q., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1206631 · Cited by 16
Voutsadakis, I. A. (2020) · Chinese Clinical Oncology · doi:10.21037/cco.2020.03.03 · Cited by 15
Wilson, B. E., Shen, Q., Cescon, D. W., & Reedijk, M. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1086163 · Cited by 15
Nie, X., Liu, Y., Yao, X., Zhang, Q., Huang, Y., Mattursun, K., Feng, Y., Liang, T., Yang, L., & Gao, X. (2026) · Nature Cancer · doi:10.1038/s43018-026-01125-2 · Cited by 15
Yu, H., Sfakianos, J. P., Wang, L., Hu, Y., Daza, J., Galsky, M. D., Sandhu, H. S., Elemento, O., Faltas, B. M., Farkas, A. M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0130 · Cited by 15
Loeuillard, E. J., Li, B., Stumpf, H. E., Yang, J., Willhite, J., Tomlinson, J. L., Wang, J., Rohakhtar, F. R., Simon, V. A., Graham, R. P., et al. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.01.006 · Cited by 15
Brajer-Luftmann, B., Nowicka, A., Kaczmarek, M., Wyrzykiewicz, M., Yasar, S. J., Piorunek, T., Sikora, J., & Batura‐Gabryel, H. (2019) · Journal of Immunology Research · doi:10.1155/2019/9708769 · Cited by 15
Kefas, J., & Flynn, M. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.67 · Cited by 14
Shirasuna, K., Ito, M., Matsuda, T., Enomoto, T., Ohara, Y., Yamamoto, M., Nishijima, S., Ohkohchi, N., & Kuromitsu, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243643 · Cited by 14
Giovannini, C., Suzzi, F., Tovoli, F., Bruccoleri, M., Marseglia, M., Alimenti, E., Fornari, F., Iavarone, M. A., Piscaglia, F., & Gramantieri, L. (2023) · Cancers · doi:10.3390/cancers15061661 · Cited by 14
Immune Checkpoint Inhibitors in Melanoma
Cooper, A. J., Carlino, M. S., & Kefford, R. F. (2015) · Melanoma Management · doi:10.2217/mmt.15.17 · Cited by 14
Savardekar, H., Allen, C., Jeon, H., Li, J., Quiroga, D. M., Schwarz, E. J., Wu, R. C. H., Zelinskas, S., Lapurga, G., Abreo, A., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0572 · Cited by 14
Metadata
- Authors
- Meyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., & Speiser, D. E.
- Affiliations
- University of Lausanne (CH)
- Centre Hospitalier Universitaire Vaudois (CH)
- Corresponding author
- Speiser, Daniel E.
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2013-12-20
- Volume
- 63
- Issue
- 3
- Pages
- 247-257
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11029062
- OpenAlex
- W2080886891
- Cited by
- 560
- References
- 58
- Citations by year
- 2026: 12 · 2025: 37 · 2024: 29 · 2023: 59 · 2022: 64 · 2021: 73 · 2020: 85 · 2019: 49 · 2018: 36 · 2017: 36 · 2016: 33 · 2015: 25 · 2014: 18 · 2013: 1
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- reroDoc Digital Library (submittedVersion)
- IRIS (submittedVersion)
- Funders
- National Science Foundation
- Ludwig Institute for Cancer Research
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (141879, 135553, 310030)
- Fondation ISREC
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- myeloid-derived suppressor cells, metastatic melanoma, ipilimumab, CTLA-4 blockade, predictive biomarkers, treatment response, monocytic MDSCs, tumor resection, lactate dehydrogenase, immune monitoring
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Cell Count, Female, Humans, Immune Tolerance, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Skin Neoplasms, Treatment Outcome, Lipopolysaccharide Receptors, Myeloid Cells, Biomarkers, Pharmacological, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.